Skip to content
Open access

Swertiamarin Ameliorates HFD+DMN-Induced Hepatic Steatosis and Fibrosis Markers via Downregulation of ASK1/MAPK Signaling Pathway

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 21 references

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) and liver fibrosis are major health concerns globally, especially in patients with type 2 diabetes mellitus (T2DM). Dysregulated insulin signaling and chronic inflammation are central to disease progression. Objective: This study evaluates the hepatoprotective and anti-fibrotic efficacy of Swertiamarin, a secoiridoid glycoside from Enicostemma littorale , in a rat model of diet-and toxin-induced liver injury. Methods: Hepatic injury and fibrosis were induced in Wistar rats using a high-fat diet (HFD) in combination with dimethylnitrosamine (DMN). The protective effects of Swertiamarin (100 mg/kg) were compared with the ASK1 inhibitor Selonsertib (50 mg/kg). Key biochemical, histological, and molecular endpoints were evaluated. Results: Swertiamarin (100 mg/kg) significantly attenuated hepatic steatosis and fibrosis, reduced insulin resistance, and lowered pro-inflammatory cytokine levels. Mechanistically, Swertiamarin downregulated the ASK1/MAPK signaling pathway and suppressed the expression of α-SMA and collagen I. Conclusion: Swertiamarin demonstrates promising anti-fibrotic and anti-inflammatory properties via ASK1/MAPK inhibition, offering a natural alternative to current pharmacological approaches for NAFLD-associated fibrosis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.